Liver Cancer Trial, Recruiting NCT06595108 Sponsor: Yonsei University Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT06595108
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 19 and 80 years old
  • People whose liver is functioning at a level that doctors classify as "Child-Pugh class A," meaning the liver is still working reasonably well (confirm with trial site)
  • People with a physical fitness and activity level that falls within a range doctors describe as ECOG 0-1, meaning they are either fully active or have only minor limitations in daily activities (confirm with trial site)
  • People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer) either through clinical assessment or confirmed by a tissue biopsy
  • People whose liver cancer is at an advanced stage and cannot be removed by surgery
  • People whose cancer is a suitable size and location for radiation therapy, and whose healthy organs can be protected within safe radiation dose limits

Who may not be able to join:

  • People whose cancer has spread to the brain
  • People who have had another type of cancer within the last 5 years, unless it was a very low-risk cancer such as certain treated cervical, skin, prostate, or uterine cancers
  • People who have untreated swollen veins in the stomach or food pipe (varices) that carry a high risk of bleeding
  • People with serious medical conditions that are not well controlled
  • People who have previously had a liver transplant
  • People who have an autoimmune liver disease, where the immune system attacks the liver

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Hwakyung BYUN, Phd, Severance Hospital

Phone: 007981072098955

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
28 May 2024
Est. completion
25 April 2027

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Progression-free survival at 6 month

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov